CD34 and systemic sclerosis: For patients with systemic sclerosis treated with HCT, TRM is considered to be related with the transplant regimen and, thus, cardiotoxicity (46), the optimal regimen for mobilization and conditioning (13), the selection or not of CD34 + graft (34), and the lack of unanimous HCT eligibility criteria.